LCN12
Epididymal-specific lipocalin-12
Also known as: LCN12_HUMAN, MGC48935
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6JVE5
- Gene
- LCN12
- Ensembl
- ENSG00000184925
- Chromosome
- 9
- Canonical length
- 192 aa
- Protein class
- Predicted intracellular proteins, Predicted secreted proteins
- Secretome location
- Secreted in male reproductive system
OverviewNCBI Gene
Members of the lipocalin family, such as LCN12, have a common structure consisting of an 8-stranded antiparallel beta-barrel that forms a cup-shaped ligand-binding pocket or calyx. Lipocalins generally bind small hydrophobic ligands and transport them to specific cells (Suzuki et al., 2004 [PubMed 15363845]).[supplied by OMIM, Aug 2009]
Canonical amino-acid sequenceUniProt
192 residues, UniProt reviewed canonical sequence.
>Q6JVE5|LCN12
1 MRLLCGLWLW LSLLKVLQAQ TPTPLPLPPP MQSFQGNQFQ GEWFVLGLAG NSFRPEHRAL
61 LNAFTATFEL SDDGRFEVWN AMTRGQHCDT WSYVLIPAAQ PGQFTVDHGV EPGADREETR
121 VVDSDYTQFA LMLSRRHTSR LAVLRISLLG RSWLLPPGTL DQFICLGRAQ GLSDDNIVFP
181 DVTGWSPQAS VCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LCN12 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 75 nTPM
Expression across tissuesHPA
Tissue
- epididymis: 75 nTPM
- thyroid gland: 6.9 nTPM
- fallopian tube: 3.2 nTPM
- cervix: 2.7 nTPM
- kidney: 2.1 nTPM
- seminal vesicle: 1.8 nTPM
Single-cell type
- epididymal principal cells: 2,624 nCPM
- epididymal efferent duct absorptive cells: 236 nCPM
- endometrial luminal cells: 103 nCPM
- epididymal clear cells: 100 nCPM
- epididymal efferent duct ciliated cells: 69 nCPM
- fallopian secretory cells: 59 nCPM
Immune cell
- plasmacytoid DC: 0.2 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- medulla oblongata: 1.9 nTPM
- cerebral cortex: 0.9 nTPM
- choroid plexus: 0.9 nTPM
- midbrain: 0.9 nTPM
- spinal cord: 0.7 nTPM
- thalamus: 0.7 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.33
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.61
- DepMap mean gene effect
- 0.1
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LCN12 as an antibody target. Whether an autoantibody or antibody against LCN12 could matter depends on whether native LCN12 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LCN12 is annotated as secreted, so native LCN12 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label LCN12 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...